The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1513
ISSUE1513
January 30, 2017
Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes
Download PDF: US English
Med Lett Drugs Ther. 2017 Jan 30;59(1513):26
Disclosures
Objective(s)
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)
In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination of insulin degludec and albiglutide; Xultophy 100/3.6 is a combination of insulin degludec and liraglutide.
Another Insulin Glargine (Basaglar) for Diabetes (Med Lett Drugs Ther 2017; 59:3)
In the Dosage and Administration section, we removed the word "syringe" to describe Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article